Figure 1.

SCr changes in Phase 3 studies. (A) Mean (┬▒SE) change from baseline in SCr (mg/dl) across the Phase 3 program (0 to 12 months). (B) SCr outliers during tofacitinib 5 mg BID treatment. (C) SCr outliers during tofacitinib 10 mg BID treatment.

Isaacs et al. Arthritis Research & Therapy 2014 16:R158   doi:10.1186/ar4673
Download authors' original image